150 related articles for article (PubMed ID: 10994377)
21. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Francobandiera G
Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
[TBL] [Abstract][Full Text] [Related]
22. Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.
Bizouard P; Vandel S; Kantelip JP
Therapie; 2001; 56(4):443-5. PubMed ID: 11677871
[No Abstract] [Full Text] [Related]
23. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.
Weigmann H; Gerek S; Zeisig A; Müller M; Härtter S; Hiemke C
Ther Drug Monit; 2001 Aug; 23(4):410-3. PubMed ID: 11477325
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
Bogusz MJ; Krüger KD; Maier RD; Erkwoh R; Tuchtenhagen F
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(2):257-69. PubMed ID: 10517347
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.
Sathirakul K; Chan C; Teng L; Bergstrom RF; Yeo KP; Wise SD
Br J Clin Pharmacol; 2003 Aug; 56(2):184-7. PubMed ID: 12895191
[TBL] [Abstract][Full Text] [Related]
26. Olanzapine excretion in human breast milk: estimation of infant exposure.
Croke S; Buist A; Hackett LP; Ilett KF; Norman TR; Burrows GD
Int J Neuropsychopharmacol; 2002 Sep; 5(3):243-7. PubMed ID: 12366877
[TBL] [Abstract][Full Text] [Related]
27. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
Hägg S; Spigset O; Lakso HA; Dahlqvist R
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
[TBL] [Abstract][Full Text] [Related]
28. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.
Penzak SR; Hon YY; Lawhorn WD; Shirley KL; Spratlin V; Jann MW
J Clin Psychopharmacol; 2002 Aug; 22(4):366-70. PubMed ID: 12172335
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.
Jakovljević M; Sagud M; Mihaljević-Peles A
Acta Psychiatr Scand; 2003 May; 107(5):394-6; discussion 396. PubMed ID: 12752037
[TBL] [Abstract][Full Text] [Related]
30. [Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
MMW Fortschr Med; 2003 May; 145 Suppl 2():86-7. PubMed ID: 14579491
[No Abstract] [Full Text] [Related]
31. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.
Grothe DR; Calis KA; Jacobsen L; Kumra S; DeVane CL; Rapoport JL; Bergstrom RF; Kurtz DL
J Clin Psychopharmacol; 2000 Apr; 20(2):220-5. PubMed ID: 10770461
[TBL] [Abstract][Full Text] [Related]
32. Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.
Lu ML; Lin CH; Chen YC; Yang HC; Wu TH
PLoS One; 2013; 8(5):e65719. PubMed ID: 23741510
[TBL] [Abstract][Full Text] [Related]
33. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
Lucas RA; Gilfillan DJ; Bergstrom RF
Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
[TBL] [Abstract][Full Text] [Related]
34. Olanzapine. Keep an eye on this neuroleptic.
Can Fam Physician; 2000 Feb; 46():322-6, 330-6. PubMed ID: 10690489
[TBL] [Abstract][Full Text] [Related]
35. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia.
Fellows L; Ahmad F; Castle DJ; Dusci LJ; Bulsara MK; Ilett KF
Ther Drug Monit; 2003 Dec; 25(6):682-9. PubMed ID: 14639054
[TBL] [Abstract][Full Text] [Related]
36. [Long-term therapy with intuition].
MMW Fortschr Med; 2003 May; 145 Suppl 2():87. PubMed ID: 14579492
[No Abstract] [Full Text] [Related]
37. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
Nyberg S; Farde L; Halldin C
Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
D'Amico G; Cedro C; Muscatello MR; Pandolfo G; Di Rosa AE; Zoccali R; La Torre D; D'Arrigo C; Spina E
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):619-23. PubMed ID: 12787848
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography.
Weigmann H; Härtter S; Maehrlein S; Kiefer W; Krämer G; Dannhardt G; Hiemke C
J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(1):63-71. PubMed ID: 11499630
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of olanzapine in human plasma with reversed-phase high performance liquid chromatography].
Xiao H; Xie SP; Fan JX; Yao H; Han G
Se Pu; 2001 May; 19(3):281-2. PubMed ID: 12541820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
